Feb 10, 2020
Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares
Dec 23, 2019
Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program
Oct 21, 2019
Theravance Biopharma and Mylan to Present New Data on YUPELRI® (revefenacin) at the 2019 CHEST Annual Meeting
Jun 14, 2019
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories
May 20, 2019
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference
Feb 27, 2018
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Feb 20, 2018
Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
Feb 07, 2018
Janssen Enters Into Worldwide Collaboration With Theravance Biopharma For Oral, Pan-JAK Inhibitor Drug Candidate For The Treatment Of Inflammatory Bowel Disease
Jan 29, 2018
Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Nov 28, 2017
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy Ellipta
Nov 21, 2017
Theravance Biopharma to Present at Two Upcoming Investor Conferences
Nov 16, 2017
Theravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta as Once-Daily Single Inhaler Triple Therapy for the Treatment of COPD
Nov 13, 2017
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Nov 07, 2017
Theravance Biopharma, Inc. Reports Third Quarter 2017 Financial Results and Provides Business Update
Nov 01, 2017
Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting
Oct 31, 2017
Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR(TM) Observational Patient Registry at 2017 CHEST Annual Meeting
Oct 30, 2017
Theravance Biopharma to Report Third Quarter 2017 Financial Results on November 7, 2017
Oct 24, 2017
Theravance Biopharma to Present New Data from Studies of VIBATIV® (telavancin) and Revefenacin (TD-4208) at the 2017 CHEST Annual Meeting
Oct 09, 2017
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek(TM) 2017
Oct 03, 2017
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek(TM) 2017